Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Cabozantinib in Advanced Salivary Gland Cancer Patients
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03729297
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 187
- Registration Number
- NCT03690388
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #153, Boston, Massachusetts, United States
🇺🇸Exelixis Clinical Site #75, Pittsburgh, Pennsylvania, United States
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2022-02-16
- Target Recruit Count
- 48
- Registration Number
- NCT03685448
- Locations
- 🇦🇺
Campbelltown Hospital, Campbelltown, New South Wales, Australia
🇦🇺Box Hill Hospital - Eastern Health, Box Hill, Victoria, Australia
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03667482
- Locations
- 🇺🇸
Baptist Alliance MCI, Miami, Florida, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03635892
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 118
- Registration Number
- NCT03634540
- Locations
- 🇺🇸
Tennessee Oncology, PLLC ( Site 0024), Chattanooga, Tennessee, United States
🇺🇸Swedish Cancer Institute ( Site 0018), Seattle, Washington, United States
🇺🇸Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0035), Seattle, Washington, United States
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-07-14
- Target Recruit Count
- 6
- Registration Number
- NCT03630120
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Peter Zage
- Target Recruit Count
- 18
- Registration Number
- NCT03611595
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT03586973
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
🇯🇵Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
- Conditions
- Malignant Neoplasms of Urinary TractRenal Cell CarcinomaMetastatic Renal Cell CarcinomaRenal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene FusionsStage IV Renal Cell Cancer AJCC v8Unclassified Renal Cell CarcinomaChromophobe Renal Cell CarcinomaPapillary Renal Cell CarcinomaSarcomatoid Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03541902
- Locations
- 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Regional Care Center-Katy, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.